--- title: GNA Biosolutions closes $13.5M series C financing round backed by a US/EU consortium description: GNA Biosolutions, a molecular diagnostics company, announced today that it has completed a $13.5M round of financing. The Series C financing round was joined by new investors and existing investors. P image: https://news.lifesciencenewswire.com/hubfs/logo_gna.png --- [![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/) - [Newsroom](https://news.lifesciencenewswire.com/newsroom) - [Back to the main site](https://lifesciencenewswire.com/) ![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1") # Newsroom #### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow") #### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg) ![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg) ### Choose a Category - [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture) - [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry) - [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing) - [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma) - [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing) - [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology) - [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture) - [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics) - [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research) - [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials) - [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it) - [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor) - [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19) - [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory) - [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development) - [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment) - [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients) - [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage) - [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry) - [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory) - [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science) - [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare) - [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management) - [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science) - [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing) - [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science) - [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) - [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control) - [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging) - [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech) - [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics) - [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology) - [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma) - [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy) - [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research) - [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary) - [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water) See all ### Subscribe to Email Updates - ##### SHARE - - - # [GNA Biosolutions closes $13.5M series C financing round backed by a US/EU consortium](https://news.lifesciencenewswire.com/newsroom/biotechnology/gna-biosolutions-closes-13-5m-series-c-financing-round-backed-by-a-us-eu-consortium) August 5, 2019 Funding will finance further development and IVD-CE marking of the company's first molecular POC (Point of Care) platform, based on Pulse Controlled Amplification (PCA) technology   GNA Biosolutions GmbH, a molecular diagnostics company based in Germany, announced today that it has completed a $13.5M round of financing.  The Series C financing round was joined by new investors including [GreyBird Ventures](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4621), [Occident](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4622), and [Wachstumsfonds Bayern](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4623), and existing investors [SHS Gesellschaft für Beteiligungsmanagement](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4624), [Robert Bosch Venture Capital](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4625), [UVC Partners](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4626), [Mey Capital Matrix](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4627), [KfW](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4628), and [btov Partners](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4629). Proceeds from the financing will be used to advance development and secure IVD-CE marking of GNA’s first Point of Care molecular diagnostic platform. "We are excited to work with the GNA team and look forward to supporting this stage of the company. Rapid molecular diagnostics are key to patient care across an increasingly broad range of therapeutic areas, and particularly infectious diseases. We believe PCA technology will resolve many limitations of existing molecular diagnostics, enabling fast therapeutic decisions that improve patient care," said Tom Miller, partner at GreyBird Ventures, lead investor for the round. Mr. Miller, a global healthcare industry leader and an experienced and visionary CEO, will serve as Chairman of GNA’s Board effective immediately.  "We are very appreciative of the enthusiastic response from our new investors and the continued support of our existing consortium. This Series C funding will help us execute our regulatory strategy and bring PCA to the clinic," said Federico Buersgens, co-founder and Managing Director of GNA Biosolutions. GNA plans to launch its POC platform first in the EU, followed by the US. "We believe having this unique combination of European and US investors on board gives GNA an edge – we have assembled a great consortium which will provide us not only with a tremendous depth of experience but also visibility and access to decision makers across our key launch markets" said Mr. Buersgens. GNA’s breakthrough technology allows the development of cost effective and simple-to-perform molecular diagnostic tests. The company’s prototype platform has been utilized in more than 30 assays in-house and with partners, including assays for Hospital Acquired Infections and Tuberculosis, and biothreats such as Ebola and Plague.  GNA is the winner of AACC’s 2018 [Disruptive Technology Award](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4630) and a Showcase Company in the 2019 [MedTech Innovator](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4631) Competition.   **About GNA Biosolutions** GNA Biosolutions is a private molecular diagnostics company located in Germany. Our proprietary PCA technology offers a novel, ultrafast, and cost-effective molecular diagnostic platform that captures and amplifies nucleic acids from complex clinical samples. PCA assays are being developed for a number of therapeutic areas, including infectious diseases and biothreats. The company’s first Point of Care product will be utilized for the diagnosis of antibiotic resistant Hospital Acquired Infections (HAIs) and Tuberculosis (TB). PCA technology has not been cleared or approved by European of U.S. regulatory agencies and is currently for research use only.  For more information, please visit [www.gna-bio.com](http://biostratamarketing.acemlnb.com/lt.php?s=7ccacee0dc954652bf854d1f57060727&i=419A841A193A4632)  Categories: [Omics & Genetics](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics), [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Diagnostics & Hospital Laboratory](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory), [Healthcare](https://news.lifesciencenewswire.com/newsroom/tag/healthcare), [Microbiology & Infection Control](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control), [Pharma](https://news.lifesciencenewswire.com/newsroom/tag/pharma), [Corporate, Finance & Investor](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor), [Medical Devices & Technology](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology) ##### Browse more news ## Recent releases #### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) July 6, 2026 Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai) #### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) June 16, 2026 New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale) #### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) June 16, 2026 Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience... ##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer) ![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse") Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225  #### Useful information - [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/) - [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions) - [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)